عندما لا يحقق التخثير الضوئي الشامل للشبكية أو علاج مضادات VEGF انحسار التوعي الجديد في اعتلال الشبكية التكاثري عالي الخطورة أو الجلوكوما الوعائية الجديدة

References

• When new vessels are accompanied by vitreous hemorrhage, or when NVD occupy greater than or equal to about one-quarter to one-third disc area, even in the absence of vitreous hemorrhage, PDR is considered high-risk.
• Patients with neovascular glaucoma or high-risk PDR should receive prompt treatment with anti-VEGF agents and PRP (see Care Process and Glossary).
• Additional PRP and/or anti-VEGF therapy should be considered in situations involving the following: failure of the neovascularization to regress; increasing neovascularization of the retina or iris; new vitreous hemorrhage; new areas of neovascularization.